These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29950894)

  • 21. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment.
    Bhatta B; Luz I; Krueger C; Teo FX; Lane DP; Sabapathy K; Cooks T
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant p53: One, No One, and One Hundred Thousand.
    Walerych D; Lisek K; Del Sal G
    Front Oncol; 2015; 5():289. PubMed ID: 26734571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer.
    Sasai K; Treekitkarnmongkol W; Kai K; Katayama H; Sen S
    Front Oncol; 2016; 6():247. PubMed ID: 27933271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of p53 Signaling in Colorectal Cancer.
    Liebl MC; Hofmann TG
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33924934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
    Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
    Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting mutant p53 in cancer: the latest insights.
    Di Agostino S; Fontemaggi G; Strano S; Blandino G; D'Orazi G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):290. PubMed ID: 31277687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1.
    Fang L; Du WW; Lyu J; Dong J; Zhang C; Yang W; He A; Kwok YSS; Ma J; Wu N; Li F; Awan FM; He C; Yang BL; Peng C; MacKay HJ; Yee AJ; Yang BB
    Cell Death Differ; 2018 Dec; 25(12):2195-2208. PubMed ID: 29795334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O
    Cordani M; Butera G; Dando I; Torrens-Mas M; Butturini E; Pacchiana R; Oppici E; Cavallini C; Gasperini S; Tamassia N; Nadal-Serrano M; Coan M; Rossi D; Gaidano G; Caraglia M; Mariotto S; Spizzo R; Roca P; Oliver J; Scupoli MT; Donadelli M
    Br J Cancer; 2018 Oct; 119(8):994-1008. PubMed ID: 30318520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 signaling in cancer progression and therapy.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Morrione A; Giordano A; Cenciarelli C
    Cancer Cell Int; 2021 Dec; 21(1):703. PubMed ID: 34952583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
    Adhikari AS; Iwakuma T
    Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptome profiling identifies genes and pathways deregulated upon floxuridine treatment in colorectal cancer cells harboring GOF mutant p53.
    Datta A; Dey S; Das P; Alam SK; Roychoudhury S
    Genom Data; 2016 Jun; 8():47-51. PubMed ID: 27114909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posttranslational phosphorylation of mutant p53 protein in tumor development.
    Matsumoto M; Furihata M; Ohtsuki Y
    Med Mol Morphol; 2006 Jun; 39(2):79-87. PubMed ID: 16821145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the
    Chitrala KN; Nagarkatti M; Nagarkatti P; Yeguvapalli S
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer.
    Kim MP; Zhang Y; Lozano G
    Front Oncol; 2015; 5():249. PubMed ID: 26618142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.